Photo: The White House from Washington, DC | Public domain | Wikimedia Commons
Joe Rogan Text Helped Precipitate Trump Order Fast-Tracking FDA Psychedelic Reviews
Joe Rogan's text to former President Donald Trump helped prompt a White House executive order fast-tracking FDA reviews of certain psychedelics.
Trump signed the order in the Oval Office on April 18, 2026, directing faster review and research into ibogaine, psilocybin, MDMA and LSD for PTSD and other mental health conditions. Trump publicly credited Rogan at the signing and, according to accounts, replied to Rogan's text, "Sounds great. Do you want FDA approval? Let's do it."
The order tasks the Food and Drug Administration with issuing national priority vouchers for three psychedelics, which officials say can cut review times from months to weeks. The administration also directed $50 million toward ibogaine research and signaled it would open a pathway for some desperately ill patients under the FDA's Right To Try rule. Officials said FDA will begin the process to clear the way for the first ibogaine human trials in the United States, even though ibogaine remains a Schedule I drug. Scientists and public health experts note the evidence base is limited to small studies and one randomized trial, with larger trials only beginning and regulators warning of cardiac risks. A 2023 review called ibogaine's heart risks "worrying," and health records link the drug to at least 27 deaths from cardiac arrhythmias.
Early mainstream coverage framed the order as an innovative push to help veterans and people with severe mental illness, highlighting veteran supporters and research promise. PBS, CBS and NPR emphasized rapid access, veterans' trials and President Trump's pledge that approvals could have a "tremendous impact" if the drugs prove effective. Subsequent reporting, led notably by Fox News and other outlets, shifted attention toward safety concerns, limited evidence for ibogaine and concerns about politicizing approval. That newer coverage amplified details such as Rogan standing behind Trump at the signing, his text exchange with the president, and warnings from critics including Kevin Sabet and researchers about cardiac risks.
Donald Trump
FDA and Drug Policy
Psychedelic Medicine
Drug Policy and Psychedelic Research
Veterans' Mental Health
This story is compiled from 9 sources using AI-assisted curation and analysis. Original reporting is attributed below. Learn about our methodology.
📌 Key Facts
- On April 18, 2026, President Trump signed an executive order in the Oval Office to fast-track research, funding and potential FDA approval of psychedelics, explicitly easing federal restrictions to accelerate access for PTSD, depression and addiction.
- The order names ibogaine, psilocybin, MDMA and LSD and directs the FDA to support clinical trials and speed reviews, including adding three psychedelics to the National Priority Voucher pilot program to cut review times from months to weeks — the first time psychedelics have been fast-tracked this way.
- The administration committed $50 million in federal research funding (with specific emphasis on ibogaine) and opened a pathway for 'desperately ill' patients to access ibogaine under the FDA's Right To Try rules.
- President Trump credited a private text from podcaster Joe Rogan about ibogaine as the immediate catalyst: Rogan says he texted Trump about its reported success treating opioid addiction and Trump replied, 'Sounds great. Do you want FDA approval? Let's do it.' Rogan stood behind Trump at the signing and officials described a rapid policy sprint that turned the exchange into an order within days.
- The order requires the Department of Veterans Affairs to begin psychedelics research and clinical trials and to make therapies available to veterans who have not responded to SSRIs and talk therapy; the VA is already participating in at least five psychedelic trials in New York, California and Oregon.
- Scientific evidence for ibogaine is limited — consisting mainly of small studies and one randomized trial with larger trials only beginning — and experts warn of substantial safety concerns, particularly cardiotoxicity: ibogaine is a Schedule I drug linked to at least 27 deaths from cardiac arrhythmias and prior NIH-funded work was halted over cardiovascular risks.
- The Oval Office signing included advocates and political figures (including Joe Rogan, Americans for Ibogaine CEO W. Bryan Hubbard and former Energy Secretary Rick Perry); veteran advocates and some clinicians praised the move, while drug-policy experts and public-health voices cautioned about limited evidence, politicization and the need for careful dosing and research.
- Administration officials, including FDA Commissioner Makary and CMS Administrator Mehmet Oz, framed the initiative as part of a broader health agenda and said the national priority vouchers and other steps could allow approvals within weeks if products prove safe and effective.
📰 Source Timeline (9)
Follow how coverage of this story developed over time
April 20, 2026
5:32 PM
Joe Rogan reveals text to Trump that helped expedite federal review of psychedelics
New information:
- Joe Rogan says he texted Trump about ibogaine's reported success treating opioid addiction, and Trump replied, 'Sounds great. Do you want FDA approval? Let's do it.'
- The article portrays that private text exchange as the immediate trigger that sped up the policy process leading to the executive order.
- CMS Administrator Mehmet Oz describes the internal follow-through as a 'rapid policy sprint,' translating the Rogan-Trump exchange into a formal order in days.
- The piece emphasizes Trump's public praise of Rogan at the Oval Office signing, calling him 'an amazing guy' and citing his note as prompting the review.
April 19, 2026
6:18 PM
Full transcript of "Face the Nation with Margaret Brennan," April 19, 2026
New information:
- Face the Nation’s rundown highlights Trump’s psychedelic executive order as part of a broader push to 'make America healthy again' and pairs it with news of his CDC director pick, framing both as a coordinated health agenda.
- The show teases an interview with former Surgeon General Jerome Adams to explain the implications of loosening psychedelic restrictions and the new CDC appointment, signaling that mainstream medical voices see both moves as consequential and politically fraught.
1:00 PM
Trump-backed plan could fast-track psychedelic therapies — here’s what to know
New information:
- Article reiterates that Trump signed an April 18, 2026 executive order to fast-track research, funding and potential FDA approval of ibogaine, psilocybin, LSD and MDMA for PTSD, depression and addiction.
- It states that the executive order will require the Veterans Affairs health system to begin psychedelics research and clinical trials and make those therapies available to veterans who have not responded to SSRIs and talk therapy.
- Provides on-the-record reaction from Jay Kopelman, former Marine Corps lieutenant colonel and CEO of Mission to Live Foundation, calling the order a pathway to expedited approval for treatment-resistant PTSD, TBI and depression.
- Includes comments from Fox medical contributor Dr. Marc Siegel saying psychedelics hold 'big potential' for severe depression and PTSD by modulating dopamine and serotonin but stressing the need for more research and careful dosing.
- Features praise from veteran advocate Juliana Mercer of Healing Breakthrough, who frames the move as a meaningful step for veterans who have tried years of therapy and medications without relief.
- Introduces critical perspective from drug-policy figure Kevin Sabet, who warns about limited evidence and politicization around ibogaine (partially visible in the excerpt but clearly present as a counterpoint).
April 18, 2026
6:56 PM
Trump signs order fast tracking review of psychedelics for mental health disorders
New information:
- NPR pins the signing to Saturday, April 18, 2026, and describes it as taking place in the Oval Office with specific participants present.
- The story specifies that Trump directed $50 million in federal funds to make certain psychedelics more accessible for mental health treatment.
- It clarifies that the executive order tasks FDA with fast tracking reviews of psilocybin and ibogaine and that ibogaine and psilocybin remain Schedule I drugs under DEA rules.
- FDA Commissioner Mary Makary is quoted as saying national priority vouchers for three psychedelics will allow approvals within weeks, and that this is the first time FDA has fast tracked any psychedelics.
- The article adds context on a 2025 JAMA study finding a single LSD dose eased anxiety and depression for months and restates national prevalence figures for serious mental illness, depression, and generalized anxiety disorder.
- It confirms that the Department of Veterans Affairs is participating in at least five psychedelic trials in New York, California, and Oregon.
5:00 PM
Trump signs executive order on psychedelic drugs — with Joe Rogan by his side
New information:
- Trump signed the executive order in the Oval Office with Joe Rogan standing directly behind him and publicly credited Rogan's call as a catalyst, saying Rogan told him 'We have to do something about this.'
- The order explicitly lists ibogaine, psilocybin, MDMA and LSD as psychedelics the FDA is directed to support in clinical trials and speed toward approval if found safe and effective.
- Rogan said he learned about ibogaine's potential from a podcast interview with Americans for Ibogaine CEO W. Bryan Hubbard and former Energy Secretary Rick Perry, both present at the signing.
- Trump joked about wanting ibogaine himself and cited a study he said showed major reductions in depression and anxiety symptoms within a month for people who took the drug.
- The article underscores that Rogan has recently criticized Trump on immigration, the Epstein files and the Iran war, yet appeared friendly with him at the signing, with Trump calling him a 'fantastic person.'
4:30 PM
Watch: Trump signs executive order easing U.S. restrictions on psychedelic research
New information:
- CBS clip confirms Trump signed an executive order specifically described as easing U.S. restrictions on psychedelic research.
- CBS explicitly frames ibogaine as a psychedelic used in some countries to treat post-traumatic stress disorder.
4:27 PM
Trump signs order to hasten review of psychedelics
New information:
- Confirms the order was signed Saturday, April 18, 2026, in the Oval Office.
- Details that FDA will issue new national priority vouchers for three psychedelics, cutting review times from months to weeks, marking the first time psychedelics receive this fast-tracking.
- States FDA is taking steps to clear the way for the first-ever ibogaine human trials in the United States.
- Quotes Trump promising to "dramatically accelerate" access and saying if the drugs are as good as advocates claim they will have a "tremendous impact."
- Reports that Joe Rogan personally texted Trump about ibogaine and that Trump replied, "Sounds great. Do you want FDA approval? Let's do it."
- Includes on-the-record enthusiasm from veteran Marcus Luttrell and explicit acknowledgment from researchers like Frederick Barrett about ibogaine's cardiotoxicity and past NIH funding being halted over cardiovascular risks.
1:46 PM
Trump signs order to research psychedelic used abroad to treat PTSD
New information:
- Executive order explicitly eases federal restrictions on ibogaine and is framed around post-traumatic stress disorder treatment, especially for veterans.
- Trump announces a $50 million federal research investment specifically for ibogaine.
- The administration will open a pathway for ibogaine use by 'desperately ill' patients under FDA's Right To Try rule.
- FDA Commissioner Marty Makary says three psychedelics will be added to the National Priority Voucher pilot program to cut review times.
- FDA will begin the process to allow human trials of ibogaine in the United States.
- Scientific evidence for ibogaine remains limited to small studies and one randomized trial, with only early larger trials underway.
- Ibogaine is a Schedule I drug associated with at least 27 deaths from cardiac arrhythmias, and a 2023 review called heart risks 'worrying.'